Backed by a conglomerate that has pharma expertise, Rome based Angelini Ventures has a $300M fund that invests broadly in life sciences and healthcare

blonca9
Oct 18, 2024
1 min read

Medical Director Fabrizio Calisti describes the fund, its foundation in the CNS but broad interest today, current portfolio holdings, and his take on biotech in the area.

Recent Posts

See All

As federal funding for cancer research has been jeopardized at NIH and academia, Parker Institute for Cancer Immunotherapy is one private institution ready to step up and broaden its impact

Mount Sinai has embraced AI as a drug discovery tool by launching this month its new AI Small Molecule Drug Discovery Center - Professor Avner Schlessinger tells us why

Jones Healthcare & Technology Innovation Conference: Jones Research analysts Soumit Roy and Justin Walsh share their take on biotech and comment on companies they cover

Backed by a conglomerate that has pharma expertise, Rome based Angelini Ventures has a $300M fund that invests broadly in life sciences and healthcare

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight